MBA from University of Chicago; PhD in molecular biology from Medical College of Columbia University; Bachelor in Biology from Peking University

Years of successful management and investment experience in medicine and medical devices industries.

Executive Director, Riverhead Capital:

Managing Director, Korean Investment Partners

Executive Director/Partner, ePlanet Ventures

Executive Director, Mingxin China Growth Fund: 

Co-founder/Director, Eastwin Life Sciences: 

Senior Consultant, McKinsey

Awards and Honors

Top 100 Best Healthcare Investors, Qiming Technology, 24 Xinsheng

Creative Bioscience, Life Real, Shuwen, iXING, Dymind, HealthCare, DeepCyto, Jiankang, AIVFO, Innovita, YHLO (688575), Yingsheng, Rainsure, XABT, Tongshu Gene, Genskey, Panomix, H-Bio, Quantum Si (Nasdaq: QSI), Rongchang Bio (688331; HK9995), Pegbio, Yinglian Biopharma, Sorrento (Nasdaq: SRNE), iKang, 91huayi, First BCC, More, Kangfu Zhijia, Alltech, Mingsite, Yongyuan Shengwu, GumpTech, IAT, Kejingyuan, Xpeedic Technology, Caishuo